Design of crRNA to Regulate MicroRNAs Related to Metastasis in Colorectal Cancer Using CRISPR-C2c2 (Cas13a) Technique

Document Type : Short Communication


1 Department of Biology, Faculty of Basic Sciences, Qaemshahr Branch, Islamic Azad University, Mazandaran, Iran

2 Young Researchers and Elite Club, Qaemshahr Branch, Islamic Azad University, Mazandaran, Iran

3 Department of Medical Laboratory Sciences, Faculty of Medical Sciences, Gorgan Brach, Islamic Azad University, Golestan, Iran

4 ZistFanavari Novin Biotechnology Institute, Isfahan, Iran


Colorectal cancer (CRC) is the third most prevalent cancer with the second-highest mortality rate worldwide. microRNAs
(miRNAs) of cancer-derived exosomes have shown promising diagnosis potential. Recent studies have shown the
metastatic potential of a specific group of microRNAs called metastasis. Therefore, down-regulation of miRNAs at the
transcriptional level can reduce metastasis probability. The aim of this bioinformatics research is targeting of miRNAs
precursors using CRISPR-C2c2 (Cas13a) technique. The C2c2 (Cas13a) enzyme structure was downloaded from
the RCSB database, the sequence miRNAs and their precursors were collected from miRbase. The crRNAs were
designed and evaluated for their specificity by using CRISPR-RT server. The modeling 3D structure of the designed
crRNA was performed by RNAComposer server. Finally, HDOCK server was used to perform molecular docking to
evaluate docked molecules' energy level and position. The crRNAs designed for miR-1280, miR-206, miR-195, miR-
371a, miR-34a, miR-27a, miR-224, miR-99b, miR-877, miR-495 and miR-384 that showed high structural similarity
with the situation observed in normal and appropriate orientation was obtained. Despite high specificity, the correct
orientation was not established in the case of crRNAs that designed to target miR-145, miR-378a, miR-199a, miR-
320a and miR-543. The predicted interactions between crRNAs and Cas13a enzyme showed that crRNAs have a
strong potential to inhibit metastasis. Therefore, crRNAs may be considered as an effective anticancer agent for further
research in drug development.


Main Subjects

  1. Barani M, Bilal M, Rahdar A, Arshad R, Kumar A, Hamishekar H, et al. Nanodiagnosis and nanotreatment of colorectal cancer: an overview. J Nanopart Res. 2021; 23(1): 1-25.
  2. Lauby-Secretan B, Vilahur N, Bianchini F, Guha N, Straif K; International Agency for Research on Cancer Handbook Working Group. The IARC perspective on colorectal cancer screening. N Engl J Med. 2018; 378(18): 1734-1740.
  3. Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, et al. Colorectal cancer liver metastasis: evolving paradigms and future directions. Cell Mol Gastroenterol Hepatol. 2017; 3(2): 163-173.
  4. Abudayyeh OO, Gootenberg JS, Konermann S, Joung J, Slaymaker IM, Cox DB, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science. 2016; 353(6299): aaf5573.
  5. Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, et al. Nucleic acid detection with CRISPR-Cas13a/ C2c2. Science. 2017; 356(6336): 438-442.
  6. Li Y, Li S, Wang J, Liu G. CRISPR/Cas systems towards nextgeneration biosensing. Trends Biotechnol. 2019; 37(7): 730- 743.
  7. Hu YB, Yan C, Mu L, Mi YL, Zhao H, Hu H, et al. Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance. Oncogene. 2019; 38(11): 1951-1965.
  8. Venkatesh V, Nataraj R, Thangaraj GS, Karthikeyan M, Gnanasekaran A, Kaginelli SB, et al. Targeting notch signalling pathway of cancer stem cells. Stem Cell Investig. 2018; 5: 5.
  9. Fre S, Pallavi SK, Huyghe M, Laé M, Janssen KP, Robine S, et al. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci USA. 2009; 106(15): 6309-6314.
  10. Tyagi A, Sharma AK, Damodaran C. A review on notch signaling and colorectal Cancer. Cells. 2020; 9(6): 1549.
  11. Huang R, Wang G, Song Y, Tang Q, You Q, Liu Z, et al. Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor. Mol Med Rep. 2015; 12(2): 2417-2424.
  12. Soleimani A, Pashirzad M, Avan A, Ferns GA, Khazaei M, Hassanian SM. Role of the transforming growth factor-β signaling pathway in the pathogenesis of colorectal cancer. J Cell Biochem. 2019; 120(6): 8899-8907.
  13. Xu J, Xiao Y, Liu B, Pan S, Liu Q, Shan Y, et al. Exosomal MALAT1 sponges miR-26a/26b to promote the invasion and metastasis of colorectal cancer via FUT4 enhanced fucosylation and PI3K/Akt pathway. J Exp Clin Cancer Res. 2020; 39(1): 54.
  14. Zhu H, Richmond E, Liang C. CRISPR-RT: a web application for designing CRISPR-C2c2 crRNA with improved target specificity. Bioinformatics. 2018; 34(1): 117-119.
  15. Purzycka KJ, Popenda M, Szachniuk M, Antczak M, Lukasiak P, Blazewicz J, et al. Automated 3D RNA structure prediction using the RNAComposer method for riboswitches. Methods Enzymol. 2015; 553: 3-34.
  16. Yan Y, Zhang D, Zhou P, Li B, Huang SY. HDOCK: a web server for protein-protein and protein-DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res. 2017; 45(W1): W365-W373.
  17. Lew JB, Feletto E, Wade S, Caruana M, Kang YJ, Nickson C, et al. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates. Public Health Res Pract. 2019; 29(2): 29121913.
  18. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1): 22.
  19. Brenner H, Chen C. The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention. Br J Cancer. 2018; 119(7): 785-792.
  20. Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging. 2016; 11: 967-976.
  21. Nikolouzakis TK, Vassilopoulou L, Fragkiadaki P, Mariolis Sapsakos T, Papadakis GZ, Spandidos DA, et al. Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review). Oncol Rep. 2018; 39(6): 2455-2472.
  22. Yan Y, Wen Z, Wang X, Huang SY. Addressing recent docking challenges: a hybrid strategy to integrate template-based and free protein-protein docking. Proteins. 2017; 85(3): 497-512.
  23. East-Seletsky A, O’Connell MR, Burstein D, Knott GJ, Doudna JA. RNA targeting by functionally orthogonal type VI-A CRISPR- Cas enzymes. Mol Cell. 2017; 66(3): 373-383. e3.
  24. Liu L, Li X, Wang J, Wang M, Chen P, Yin M, et al. Two distant catalytic sites are responsible for C2c2 rnase activities. Cell. 2017; 168(1-2): 121-134. e12.
  25. Vinchhi P, Patel MM. Triumph against cancer: invading colorectal cancer with nanotechnology. Expert Opin Drug Deliv. 2021; 18(9): 1169-1192.